Carna Biosciences, Inc.
Notice Regarding Recording of Non-Operating Expenses and Extraordinary Losses
In the third-quarter consolidated results for the fiscal year ending December 2026, the company reported recognition of non-operating expenses (including interest paid) and extraordinary losses. Foreign exchange losses decreased. Impairment loss amounted to 7,406 thousand yen. These items are reflected in the third-quarter financial summary for the fiscal year ending December 2026.
Key Figures
- Interest paid: 19,108 thousand yen
- Issuance costs of bonds with stock acquisition rights: 4,451 thousand yen
- Foreign exchange gains: 4,267 thousand yen
- Cumulative foreign exchange losses: 4,845 thousand yen
- Impairment loss: 7,406 thousand yen
AI要約
Key Points of the Financial Results
During the third-quarter consolidated period, non-operating expenses included interest paid, primarily due to amortization and interest on convertible bonds with stock acquisition rights. Issuance costs for bonds with stock acquisition rights were also recorded. Foreign exchange losses decreased due to exchange rate fluctuations, and foreign exchange gains were recorded in some periods. Foreign exchange losses for the third-quarter cumulative period totaled 4,845 thousand yen. Assets showing signs of impairment were written down to their recoverable amounts, and an impairment loss of 7,406 thousand yen was recorded. These items are reflected in the third-quarter financial summary for the fiscal year ending December 2026.
Future Impact and Notes
The above expense and loss recordings may affect indicators such as ordinary income for the current term; however, the main text does not specify concrete levels of revenue or operating income. Detailed financial indicators will be published in the financial summary, and investors should await the disclosure of that financial summary.
Carna Biosciences, Inc.
Company overview · Stock price · Financial data · All IR
